Abstract:Background Theranostic nanoplatforms with integrated diagnostic imaging and multiple therapeutic functions play a vital role in precise diagnosis and efficient treatment for breast cancer, but unfortunately, these nanoplatforms are usually stuck in single-site imaging and single mode of treatment, causing unsatisfactory diagnostic and therapeutic efficiency. Herein, a dual biomarkers-activatable facile hollow mesoporous MnO 2 (H–MnO 2 )-based theranostic nanoplatform, DNAzyme@H–MnO 2 -MUC1 aptamer (DHMM), was constructed for the simultaneous multi-site diagnosis and multiple treatment of breast cancer. Results The DHMM acted as an integrated diagnostic and therapeutic nanoplatform that realizes multi-site fluorescence imaging-guided high-efficient photothermal/chemodynamic/gene synergistic therapy (PTT/CDT/GT) for breast cancer. The H–MnO 2 exhibits high loading capacity for Cy5-MUC1 aptamer (3.05 pmoL μg −1 ) and FAM-DNAzyme (3.37 pmoL μg −1 ), and excellent quenching for the probes. In the presence of MUC1 on the cell membrane and GSH in the cytoplasm, Cy5-MUC1 aptamer and FAM-DNAzyme was activated triggering dual-channel fluorescence imaging at different sites. Moreover, the self-supplied Mn 2+ was further supplied as DNAzyme cofactors to catalytic cleavage intracellular EGR-1 mRNA for high-efficient GT and stimulated the Fenton-like reaction for CDT. The H–MnO 2 also showcases a favorable photothermal performance with a photothermal conversion efficiency of 44.16%, which ultimately contributes to multi-site fluorescence imaging-guided synergistic treatment with an apoptosis rate of 71.82%. Significance This dual biomarker-activatable multiple therapeutic nanoplatform was realized multi-site fluorescence imaging-guided PTT/CDT/GT combination therapy for breast cancer with higher specificity and efficiency, which provides a promising theranostic nanoplatform for the precision and efficiency of breast cancer treatment.

A Folate-Conjugated Dual-Modal Fluorescent Magnetic Resonance Imaging Contrast Agent That Targets Activated Macrophages in Vitro and in Vivo.

Ultra-Small and Metabolizable Near-Infrared Au/Gd Nanoclusters for Targeted FL/MRI Imaging and Cancer Theranostics

A Novel TMTP1-modified Theranostic Nanoplatform for Targeted in Vivo NIR-II Fluorescence Imaging-guided Chemotherapy of Cervical Cancer

Targeted Fluorescent Magnetic Nanoparticles for Imaging of Human Breast Cancer.

Magnetic resonance molecular imaging of metastatic breast cancer by targeting extradomain-B fibronectin in the tumor microenvironment.

Folate Receptor Targeting Mn(II) Complex Encapsulated Porous Silica Nanoparticle as an MRI Contrast Agent for Early‐State Detection of Cancer

Tumor-targetable magnetoluminescent silica nanoparticles for bimodal time-gated luminescence/magnetic resonance imaging of cancer cells in vitro and in vivo

In Vivo Tumor Vasculature Targeted Pet/Nirf Imaging with Trc105(Fab)-Conjugated, Dual-Labeled Mesoporous Silica Nanoparticles

Multiple functional nanoprobe for contrast-enhanced bimodal cellular imaging and targeted therapy.

Ph-Responsive Iron Manganese Silicate Nanoparticles As T1-T2* Dual-Modal Imaging Probes for Tumor Diagnosis.

Dual-Mode Contrast Agents with RGD-Modified Polymer for Tumour-Targeted US/NIRF Imaging

Dual-Modality Imaging Probes with High Magnetic Relaxivity and Near-Infrared Fluorescence Based Highly Aminated Mesoporous Silica Nanoparticles

In Vivo Targeted Magnetic Resonance Imaging and Visualized Photodynamic Therapy in Deep-Tissue Cancers Using Folic Acid-Functionalized Superparamagnetic-Upconversion Nanocomposites

Activatable Fluorescence/Mri Bimodal Platform for Tumor Cell Imaging Via Mno2 Nanosheet-Aptamer Nanoprobe

Development of in Vitro and in Vivo C-Met Targeted Dual-Modal Nanoprobes for NIR II Fluorescent Bioimaging and Magnetic Resonance Imaging of Breast Carcinoma Metastasis

Furin-Catalyzed Enhanced Magnetic Resonance Imaging Probe for Differential Diagnosis of Malignant Breast Cancers

Development and Characterization of an Antibody-Labeled Super-Paramagnetic Iron Oxide Contrast Agent Targeting Prostate Cancer Cells for Magnetic Resonance Imaging

Biocompatible Mesoporous Silica–Polydopamine Nanocomplexes as MR/Fluorescence Imaging Agent for Light-Activated Photothermal–Photodynamic Cancer Therapy In Vivo

Dual biomarkers-activatable hollow MnO 2 -Based theranostic nanoplatform for efficient breast cancer-specific multisite fluorescence imaging and synergistic therapy

Specific diagnosis of lymph node micrometastasis in breast cancer by targeting activatable near-infrared fluorescence imaging

Receptor-Targeted Nanoparticles for in Vivo Imaging of Breast Cancer